1729-67-5Relevant articles and documents
1,2,2-Tribromocyclopropanecarboxylic acid and derivatives - Valuable intermediates for four carbon cyclopropane and cyclopropene synthons
Al Dulayymi, Ahmad R.,Al Dulayymi, Juma'a R.,Baird, Mark S.,Gerrard, Michelle E.,Koza, Gani,Harkins, Samantha D.,Roberts, Evan
, p. 3409 - 3424 (1996)
Methyl 1,1,2-tribromocyclopropanecarboxylate is readily available by dibromocyclopropanation of methyl α-bromoacrylate. Reaction with methyllithium at low temperature provides a simple route to methyl 2-bromocyclopropene carboxylate, while modification of the ester group followed by reaction with methyllithium leads to a series of related four-carbon cyclopropenes. The tribromo-ester is also readily converted into 1,1,2,2-tetrabromocyclopropane, a valuable three-carbon cyclopropene synthon.
COMPOUNDS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS
-
Paragraph 0079, (2020/12/07)
This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.
How Reaction Conditions May Influence the Regioselectivity in the Synthesis of 2,3-Dihydro-1,4-benzoxathiine Derivatives
Casiraghi, Andrea,Valoti, Ermanno,Suigo, Lorenzo,Artasensi, Angelica,Sorvillo, Erica,Straniero, Valentina
, p. 13217 - 13227 (2018/10/24)
The exploration of different reaction conditions aiming to obtain both 2,3-dihydro-1,4-benzoxathiine-2-yl derivatives and 2,3-dihydro-1,4-benzoxathiine-3-yl ones is reported. The treatment of 1,2-mercaptophenol with an organic base and a specific 2-bromo acrylate results in a solvent- and substrate-dependent exclusive solvation of O- and S-anions, thus managing the regioselectivity.
Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil
van Greunen, Divan G.,Cordier, Werner,Nell, Margo,van der Westhuyzen, Chris,Steenkamp, Vanessa,Panayides, Jenny-Lee,Riley, Darren L.
, p. 671 - 690 (2017/02/10)
A series of twenty seven acetylcholinesterase inhibitors, as potential agents for the treatment of Alzheimer's disease, were designed and synthesised based upon previously unexplored chemical space surrounding the molecular skeleton of the drug donepezil, which is currently used for the management of mild to severe Alzheimer's disease. Two series of analogues were prepared, the first looking at the replacement of the piperidine ring in donepezil with different sized saturated N-containing ring systems and the second looking at the introduction of different linkers between the indanone and piperidine rings in donepezil. The most active analogue 5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl 1-benzylpiperidine-4-carboxylate (67) afforded an in vitro IC50value of 0.03 ± 0.07 μM against acetylcholinesterase with no cytotoxicity observed (IC50of >100 μM, SH-SY5Y cell line). In comparison donepezil had an IC50of 0.05 ± 0.06 μM and an observed cytotoxicity IC50of 15.54 ± 1.12 μM. Molecular modelling showed a strong correlation between activity and in silico binding in the active site of acetylcholinesterase.
